HighTide Therapeutics today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright Global Life Sciences Conference March 9-10, 2021.
March 01, 2021
Learn more
SHENZHEN, CHINA and ROCKVILLE, MD, February 1, 2021— HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the appointment of Leigh MacConell, Ph.D., as Chief Development Officer. Dr. MacConell has over 20 ye
February 01, 2021
Learn more
HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes
December 21, 2020
Learn more
We will contact you as soon as possible
© 2020 HighTide Therapeutics Inc.